Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)

OPAL中心的命名是因为它的目标是为患有糖尿病的人优化和个性化干预。 精神分裂症的寿命。这个ALACRITY中心的目标人群是被诊断为 精神分裂症，其通常影响从青春期或成年早期直到生命结束的个体。 受影响的个人通常有受损的社会和职业功能;经验持续 精神病和情绪症状;有可能进展的认知问题;有残疾的风险， 过早死亡黑人、土著人和有色人种（BIPOC）特别容易陷入贫困。 结果。此次更新申请的目的是扩大我们的努力，以加快发展， 在真实的临床环境中对精神分裂症实施有效的个体化治疗。 中心更新申请的具体目的如下： 1.加强我们的基础设施，支持研究，研究创新的方法，以优化 治疗精神分裂症患者的整个生命周期，并加速临床转化 精神分裂症研究的常规实践设置。 2.开展项目，开发，调整和测试创新，可访问和以人为本的干预措施 其改善了治疗中的参与并可以容易地展开。 3.培训将对精神分裂症干预措施进行转化研究的科学家。 OPAL签名项目将使用医疗补助中心16年（2007-2022）的数据， 医疗保险服务（CMS），以测试有关被诊断患有痴呆症的人的风险因素的假设。 精神分裂症，并比较痴呆诊断后治疗策略的有效性。然后我们将 整合我们的研究结果，以适应认知健康工具包，提供评估和管理工具。 探索性项目1测试了一种新的、以人为本的评估和治疗启动方法 对于在社区精神卫生诊所有精神病症状的BIPOC个体， 文化制定访谈的改编版本，以提高诊断和治疗的参与。 探索性项目2将在欧洲所做工作的基础上进行调整和测试， 灵活肯定的社区治疗（ACT）的初步效果，这将使ACT团队， 根据参与者的个人需求分配资源，提高效率和成果。 探索性项目3使用移动的健康（mHealth）技术提供基于测量的护理 并改善精神分裂症患者在整个生命周期中以人为本的结果。 该中心的项目利用该中心的共同资源和方法来改善执行情况， 针对重要问题的个性化治疗。利益相关者帮助我们完善和调整干预措施， 在现实世界中的有效实施。

The OPAL Center is named after its goal of Optimizing and Personalizing interventions for people with schizophrenia Across the Lifespan. The target population for this ALACRITY Center is people diagnosed with schizophrenia, which typically affects individuals from adolescence or early adulthood until the end of life. Affected individuals commonly have impaired social and occupational functioning; experience persistent psychotic and mood symptoms; have cognitive problems that may progress; and are at risk for disability and premature death. Black, Indigenous, and People of Color (BIPOC) individuals are particularly at risk of poor outcomes. The goal of this renewal application is to extend our efforts to accelerate the development and implementation of effective, individualized treatments for schizophrenia in real clinical settings. The specific aims of the Center renewal application are as follows: 1. Strengthen our infrastructure that supports research that examines innovative ways to optimize treatments for people with schizophrenia throughout the lifespan and that accelerates the translation of clinical research on schizophrenia to routine practice settings. 2. Conduct projects that develop, adapt, and test innovative, accessible, and person-centered interventions that improve engagement in treatment and can be readily deployed. 3. Train scientists who will conduct translational research on interventions for schizophrenia. The OPAL Signature Project will use 16 years of data (2007-2022) from the Center for Medicaid and Medicare Services (CMS) to test hypotheses about risk factors for dementia among people diagnosed with schizophrenia and compare the effectiveness of treatment strategies after diagnosis of dementia. We will then integrate our findings to adapt a Cognitive Health Toolkit that provides assessment and management tools. Exploratory Project 1 tests a novel, person-centered approach to assessment and treatment initiation for BIPOC individuals with psychotic symptoms in community mental health clinics that incorporates an adapted version of the Cultural Formulation Interview to improve diagnosis and treatment engagement. Exploratory Project 2 will build on work done in Europe to adapt and test the feasibility and preliminary effectiveness of Flexible Assertive Community Treatment (ACT), which will allow ACT teams to allocate resources according to the individual needs of participants, improving efficiency and outcomes. Exploratory Project 3 uses mobile health (mHealth) technology to deliver measurement-based care and improve the person-centered outcomes of individuals with schizophrenia across the lifespan. OPAL projects use the Center's common resources and methodologies to improve implementation and personalization of treatments for important problems. Stakeholders help us to refine and adapt interventions for effective implementation in real-world settings.